LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Eurofins Genomics Buys VBC-Biotech Businesses, Establishes Austrian Subsidiary

By LabMedica International staff writers
Posted on 18 Nov 2014
Print article
Eurofins Genomics (Ebersberg, Germany) has acquired VBC-Biotech's (Vienna, Austria) oligonucleotide synthesis and DNA sequencing businesses, and an Austrian subsidiary is being established.

Eurofins MWG Operon is an international provider of genomic services established around the core business lines next generation sequencing (NGS), custom DNA sequencing, oligonucleotides, siRNA, and gene synthesis. A team of experts and a broad range of technologies in the field of genomic services, forensics, agroscience, pharmaceutical, environmental, food and feed testing, underline the approach to offer best praxis solutions and versatile concepts.

Eurofins Genomics is the genomics division of the Eurofins Scientific Group. The Austrian subsidiary called Eurofins Genomics AT and headquartered in Vienna, will leverage Eurofins' global network, production capacity, and infrastructure. "The new direct presence in Austria will provide value to our customers by demonstration our commitment to this market," Eurofins Genomics AT Managing Director Siegfried Schnabl said in a statement. "Furthermore, Vienna will serve as a perfect hub for future business into Central and Eastern Europe and beyond."

The joint company is located in Vienna. All VBC-Biotech's services have been integrated into the Eurofins Genomics business units.

Financial and other terms of the deal were not disclosed.

Related Links:

Eurofins Genomics
VBC-Biotech's


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more